9
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Tissue Converting Enzyme Inhibition and Cardiovascular Effects of Converting Enzyme Inhibitors

, , &
Pages 417-426 | Published online: 03 Jul 2009

References

  • Dzau V. Vascular renin-angiotensin: a possible autocrine or paracrine system in control of vascular function. J Cardiovasc. Pharmacol 1984; 6: 5377–5382
  • Ganten D, Lang R E, Lehmann E, Unger Th. Brain angiotensin: on the way to becoming a well-studied neuropeptide system. Biochem Pharmacol 1984; Vol 33(No 22)3523–3528
  • Campbell D J. The site of angiotensin production. J Hypertension 1985; 3: 199–207
  • Unger Th, Ganten D, Lang R E. Pharmacology of converting enzyme inhibitors: new aspects. Clin Exp Hypertension 1983; 5(7&8)1333–1354
  • Velletri P, Bean B L. The effects of captopril on rat aortic angiotensin-converting enzyme. J Cardiovasc Pharmacol 1982; 4: 315–325
  • Asaad M M, Antonaccio M J. Vascular wall Renin in spontaneously hypertensive rats. Potential relevance to hypertension. Maintenance and antihypertensive effect of captopril. Hypertension 1982; Vol 4(No 4)487–493
  • Xiang J, Linz W, Becker H, Ganten D, Lang R E, Schölkens B A, Unger Th. Effects of converting enzyme inhibitors: Ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart. Eur J Pharmacol 1985; 113: 215–223
  • Unger Th, Hübner D, Schüll B, Lang R E, Rascher W, Rettig R, Ganten D. Effect of chronic oral captopril treatment on tissue renin concentration and converting enzyme activity in stroke-prone spontaneously hypertensive rats. Hypertensive mechanisms, W Rascher, D Clough, D Ganten. Schattauer Verlag, Stuttgart-New York 1982; 768–773
  • Cohen M L, Kurz K. Angiotensin converting enzyme inhibition in tissue from spontaneously hypertensive rats after treatment with captopril or MK 421. J Pharmacol Exp Therapeutics 1982; Vol 220(No 1)63–69
  • Velletri P, Bean B. The effects of captopril on rat aortic angiotensin-converting enzyme. J Cardiovasc Pharmacol 1982; 4: 315–325
  • Unger Th, Fleck Th, Ganten D, Lang R E, Rettig R. 2-(N-(s)-1-Ethoxycarbonyl-3-phenylpropyl-L-alanyl)-(1S, 3S, 5S)-2-azabicyclo (3.3.0)octane-3-carboxylie acid (Hoe 498): Antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats. Arzneim.-Forsch./Drugs Res 1984; 34(II)1426–1430
  • Unger Th, Ganten D, Lang R E, Schölkens B A. Is tissue convering enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe49 8 and MK 421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1984; 6: 872–880
  • Unger Th, Moursi M, Ganten D, Hermann K, Lang R E. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490–3) in spontaneously hypertensive rats: Comparison with enalapril (MK 421) and ramipril (Hoe 498). J Cardiovasc Pharmacol 1986; 8: 276–285
  • Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertension 1984; 2: 277–284
  • Lanzillo J J, Dasarathy Y, Stevens J, Fanburg B L. Conversion of angiotensin I to angiotensin II by a latent endothelial cell peptidyl dipeptidase that is not angiotensin-converting enzyme. Biochem Biophys Res Commun 1986; 134(2)770–776
  • Hermann K, Lang R E, Unger Th, Bayer C, Ganten D. Combined high-performance liquid chromatography-radioimmunoassay for the characterization and quantitative measurement of neuropeptides. J Chromatography 1984; 312: 273–284
  • Ganten D, Balz W, Hense H, Jung W, Rohde A, Bayer C. Angiotensin (ANG) peptides in tissue of rabbits: characterization and regulation after nephrectomy and converting enzyme inhibitor (CEI) treatment.(Abstr). Naunyn-Schmiedeberg's Archives of Pharmacol 1985; 329: R63
  • Unger Th, Ganten D, Lang R E, Schölkens B A. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe 498 and MK 421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1985; 7: 36–41
  • van Gilst W H, de Graeff A P, Kingma J H, Wesseling H, de Langen C DJ. Captopril reduces purine loss and reperfusion arrhythmias in the rat heart after coronary artery occlusion. Eur J Pharmacol 1984; 100: 113–117
  • Linz P, Schölkens B A. Beneficial effects of converting enzyme inhibitors in ischemic rat heart. J. Cardiovasc. Pharmacol, in press
  • Hutchinson J S, Mendelsohn F AO, Doyle A E. Blood pressure responses normotensive and spontaneously hypertensive rats to intracerebroventricular and peripheral administration of captopril. Hypertension 1980; 2: 546–550
  • Stamler J F, Brody M J, Phillips M I. The central and peripheral effects of captopril (SQ14225) on the arterial pressure of the spontaneously hypertensive rat. Brain Res 1980; 186: 499–503
  • Unger Th, Kaufmann-Bühler I, Schölkens B, Ganten D. Brain converting enzyme inhibition: A possible mechanism for the antihypertensive action of captopril in spontaneously hypertensive rats. Eur J Pharmacol 1981a; 70: 467–478
  • Phillips M I, Kimura B. Converting enzyme inhibitors and brain angiotensin. J Cardiovasc Pharmacol 1986; 8: SX–SX, (in press)
  • Unger Th, Rockhold R W, Yukimura T, Rettig R, Rascher W, Ganten D. Role of kinins and substance P in blood pressure regulation of normotensive and spontaneously hypertensive rats. Central nervous system mechanisms in hypertension, J P Buckley, C M Ferrario. Raven Press, New York 1981; 115–127

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.